May 10, 2020 / NTS GMT
Dave Gentry - RedChip Companies, Inc. - Analyst
Back to Chowdhury. Thanks for being with us today.
Faz Chowdhury - Nemaura Medical Inc. - CEO & Chairman of the Board
That's my pleasure.
Questions and Answers:
Dave Gentry - RedChip Companies, Inc. - AnalystAnd you recently announced a head-to-head study with one of the major incumbents in the continuous glucose monitoring space. What can you tell us about the study?
Faz Chowdhury - Nemaura Medical Inc. - CEO & Chairman of the Board
Yes. So let me give you some background as to why we decided to start these studies. We've had discussions with a number of health insurers. Because, of course, our target is to get product reimbursement. Now when we look at the existing CGM, whether it's Dexcom or the Abbott, you've got CGMs that last for up to 10 days at a time for 14 days aside. And what we have seen is that based on anecdotal evidence, whereby individuals that have done intensive monitoring using finger prick
Trustpilot
